PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias

Alzheimer's disease (AD) is the most common form of dementia; a progressive neurodegenerative disease that currently lacks an effective treatment option. Early and accurate diagnosis, in addition to quick elimination of differential diagnosis, allows us to provide timely treatments that delay the progression of AD. Imaging plays an important role for the early diagnosis of AD. The newly emerging PET/MR imaging strategies integrate the advantages of PET and MR to diagnose and monitor AD. This review introduces the development of PET/MR imaging systems, technical considerations of PET/MR imaging, special considerations of PET/MR in AD, and the system's potential clinical applications and future perspectives in AD.

[1]  G. Delso,et al.  Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner , 2011, The Journal of Nuclear Medicine.

[2]  Sharmila Majumdar,et al.  In vivo bone and cartilage MRI using fully‐balanced steady‐state free‐precession at 7 tesla , 2007, Magnetic resonance in medicine.

[3]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[4]  Pedro Rosa-Neto,et al.  Performance testing of a fully automated, Chemiluminescent, beta-amyloid 42 assay , 2013, Alzheimer's & Dementia.

[5]  Junming Shao,et al.  Based on the Network Degeneration Hypothesis: Separating Individual Patients with Different Neurodegenerative Syndromes in a Preliminary Hybrid PET/MR Study , 2016, The Journal of Nuclear Medicine.

[6]  Yudong Zhang,et al.  Three-Dimensional Eigenbrain for the Detection of Subjects and Brain Regions Related with Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[7]  Julien Bert,et al.  PET/MR attenuation correction: where have we come from and where are we going? , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  C. Claussen,et al.  Simultaneous Mr/pet Imaging of the Human Brain: Feasibility Study 1 , 2022 .

[9]  Lutz Tellmann,et al.  Comparison of cerebral blood flow acquired by simultaneous [15O]water positron emission tomography and arterial spin labeling magnetic resonance imaging , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  John Seibyl,et al.  Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans , 2016, The Journal of Nuclear Medicine.

[11]  H. Quick,et al.  Magnetic Resonance–Based Attenuation Correction for PET/MR Hybrid Imaging Using Continuous Valued Attenuation Maps , 2013, Investigative radiology.

[12]  H. Arai,et al.  [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  M. F. Falangola,et al.  White matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer's disease☆ , 2013, NeuroImage: Clinical.

[14]  R Retkute,et al.  Improved detection of focal cortical lesions using 7T magnetisation transfer imaging in patients with multiple sclerosis. , 2014, Multiple sclerosis and related disorders.

[15]  D. Na,et al.  Preliminary Study for a Multicenter Study of Alzheimer's Disease Cerebrospinal Fluid Biomarkers , 2013 .

[16]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[17]  Giuseppe Scotti,et al.  A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment , 2005, NeuroImage.

[18]  Yvette Sheline,et al.  Resting bold fMRI differentiates dementia with Lewy bodies vs. Alzheimer's disease , 2011, Alzheimer's & Dementia.

[19]  Zein Al-Atrache,et al.  CHLAMYDIA PNEUMONIAE-INFECTED ASTROCYTES ALTER THEIR EXPRESSION OF ADAM10, BACE1, AND PRESENILIN-1 PROTEASES , 2016, Alzheimer's & Dementia.

[20]  Johan Nuyts,et al.  ML-reconstruction for TOF-PET with simultaneous estimation of the attenuation factors , 2014, 2012 IEEE Nuclear Science Symposium and Medical Imaging Conference Record (NSS/MIC).

[21]  Kewei Chen,et al.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.

[22]  Alejandro F. Frangi,et al.  Automated segmentation of cerebral vasculature with aneurysms in 3DRA and TOF-MRA using geodesic active regions: an evaluation study. , 2010, Medical physics.

[23]  Armin Kolb,et al.  Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? , 2008, Seminars in nuclear medicine.

[24]  Colin J. Mahoney,et al.  The common dementias: a pictorial review , 2013, European Radiology.

[25]  Long Jiang Zhang,et al.  PET/MRI of central nervous system: current status and future perspective , 2016, European Radiology.

[26]  Osama Sabri,et al.  PET/MR in dementia and other neurodegenerative diseases. , 2015, Seminars in nuclear medicine.

[27]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[28]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[29]  A. Goate,et al.  Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis , 2015, Biological Psychiatry.

[30]  Olivier Colliot,et al.  Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. , 2016, Brain : a journal of neurology.

[31]  U. Schoepf,et al.  Different Hippocampus Functional Connectivity Patterns in Healthy Young Adults with Mutations of APP/Presenilin-1/2 and APOEε4 , 2017, Molecular Neurobiology.

[32]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[33]  M. Mintun,et al.  Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[34]  S. Cherry,et al.  Simultaneous PET and MR imaging , 1997, Physics in medicine and biology.

[35]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[36]  E. Rabiner,et al.  Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer’s disease patients and control subjects , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  Frederik Barkhof,et al.  Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study , 2013, Neurobiology of Aging.

[38]  Ian Law,et al.  Clinical PET/MR Imaging in Dementia and Neuro-Oncology. , 2016, PET clinics.

[39]  Patrick Veit-Haibach,et al.  Workflow Considerations in PET/MR Imaging , 2014, The Journal of Nuclear Medicine.

[40]  G. Bormans,et al.  cGMP production of the radiopharmaceutical [18 F]MK-6240 for PET imaging of human neurofibrillary tangles. , 2017, Journal of labelled compounds & radiopharmaceuticals.

[41]  J. Mukherjee,et al.  Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model. , 2014, American journal of nuclear medicine and molecular imaging.

[42]  Karsten Mueller,et al.  Combined Evaluation of FDG-PET and MRI Improves Detection and Differentiation of Dementia , 2011, PloS one.

[43]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[44]  Habib Zaidi,et al.  Magnetic resonance imaging-guided attenuation correction in whole-body PET/MRI using a sorted atlas approach , 2016, Medical Image Anal..

[45]  George R Duensing,et al.  High temporal resolution retrospective motion correction with radial parallel imaging , 2012, Magnetic resonance in medicine.

[46]  Allen F. Brooks,et al.  Synthesis and Evaluation of [(18)F]RAGER: A First Generation Small-Molecule PET Radioligand Targeting the Receptor for Advanced Glycation Endproducts. , 2016, ACS chemical neuroscience.

[47]  Kazuyoshi Yajima,et al.  Brain FDG PET study of normal aging in Japanese: effect of atrophy correction , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[49]  K. Abe,et al.  Differences between the behavioral and psychological symptoms of Alzheimer's disease and Parkinson's disease , 2016, Journal of the Neurological Sciences.

[50]  B. K. Swann,et al.  PET/MR images acquired with a compact MR-compatible PET detector in a 7-T magnet. , 2007, Radiology.

[51]  K. Oguz,et al.  Default mode network connectivity is linked to cognitive functioning and CSF Aβ1-42 levels in Alzheimer's disease. , 2016, Archives of gerontology and geriatrics.

[52]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[53]  Anna Barnes,et al.  A comparison of CT- and MR-based attenuation correction in neurological PET , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  Maja A. A. Binnewijzend,et al.  Cerebral perfusion in the predementia stages of Alzheimer’s disease , 2015, European Radiology.

[55]  Christer Halldin,et al.  Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  J. Price,et al.  Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease , 2011, Neurology.

[57]  Krzysztof J. Gorgolewski,et al.  Dynamic network participation of functional connectivity hubs assessed by resting-state fMRI , 2014, Front. Hum. Neurosci..

[58]  M. Goubran,et al.  Seven-Tesla MRI and neuroimaging biomarkers for Alzheimer's disease. , 2015, Neurosurgical focus.

[59]  Valentin Riedl,et al.  The lower hippocampus global connectivity, the higher its local metabolism in Alzheimer disease , 2015, Neurology.

[60]  Kiralee M. Hayashi,et al.  Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. , 2007, Archives of neurology.

[61]  Christer Halldin,et al.  Clinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand , 2012, The Journal of Nuclear Medicine.

[62]  M. Pinzur.  Appropriate Use Criteria , 2014, Foot & ankle international.

[63]  Stefan Förster,et al.  MR-Based Attenuation Correction Using Ultrashort-Echo-Time Pulse Sequences in Dementia Patients , 2015, The Journal of Nuclear Medicine.

[64]  Raymond F. Muzic,et al.  Registration of micro-PET and high-resolution MR images of mice for monitoring photodynamic therapy , 2004, SPIE Medical Imaging.

[65]  R. Boellaard,et al.  Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany , 2014, Molecular Imaging and Biology.

[66]  J. Weuve,et al.  2016 Alzheimer's disease facts and figures , 2016 .

[67]  Ciprian Catana,et al.  Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI , 2013, Proceedings of the National Academy of Sciences.

[68]  D. Loewenstein,et al.  A Comparative Analysis of Structural Brain MRI in the Diagnosis of Alzheimer’s Disease , 2009, Behavioural neurology.

[69]  A. Lammertsma,et al.  Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase. , 2016, Nuclear medicine and biology.

[70]  A. Drzezga,et al.  Current status and future role of brain PET/MRI in clinical and research settings , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[71]  Karsten Mueller,et al.  Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI , 2013, Psychiatry Research: Neuroimaging.

[72]  J. Mukherjee,et al.  Evaluation of [11C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT , 2016, Synapse.

[73]  Johannes Kornhuber,et al.  Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease , 2016, Journal of Alzheimer's disease : JAD.

[74]  Osama Sabri,et al.  Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases , 2014, The Journal of Nuclear Medicine.

[75]  H. Arai,et al.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[76]  Ciprian Catana,et al.  MRI-Assisted PET Motion Correction for Neurologic Studies in an Integrated MR-PET Scanner , 2011, The Journal of Nuclear Medicine.

[77]  M. Schwartz,et al.  Harnessing monocyte‐derived macrophages to control central nervous system pathologies: no longer ‘if’ but ‘how’ , 2013, The Journal of pathology.

[78]  Simon J Graham,et al.  A robust method for suppressing motion-induced coil sensitivity variations during prospective correction of head motion in fMRI. , 2016, Magnetic resonance imaging.

[79]  J. Helpern,et al.  Stroke Assessment With Diffusional Kurtosis Imaging , 2012, Stroke.

[80]  H. Jadvar,et al.  Competitive advantage of PET/MRI. , 2014, European journal of radiology.

[81]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[82]  M. Sastre,et al.  Modulation of inflammation in transgenic models of Alzheimer’s disease , 2014, Journal of Neuroinflammation.

[83]  F. Niccolini,et al.  Recent imaging advances in neurology , 2015, Journal of Neurology.

[84]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[85]  L. Wahlund,et al.  The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease , 2014, Journal of internal medicine.

[86]  D. Schaart,et al.  First characterization of a digital SiPM based time-of-flight PET detector with 1 mm spatial resolution , 2013, Physics in medicine and biology.

[87]  Maged Goubran,et al.  Assessment of PET & ASL metabolism in the hippocampal subfields of MCI and AD using simultaneous PET-MR , 2015, EJNMMI Physics.

[88]  Dinggang Shen,et al.  O2-03-06 MCI diagnosis via high-dimensional pattern classification with simultaneous utilization of MR and pet-CBF images yields 100% correct classification , 2007, Alzheimer's & Dementia.

[89]  D. Bennett,et al.  Alzheimer's disease: Unique markers for diagnosis & new treatment modalities , 2015, The Indian journal of medical research.

[90]  Johan Nuyts,et al.  Transmission-less attenuation correction in time-of-flight PET: analysis of a discrete iterative algorithm , 2014, Physics in medicine and biology.

[91]  J. Barrio,et al.  Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1. , 2016, Journal of Alzheimer's disease : JAD.

[92]  Val Lowe,et al.  Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. , 2013, Brain : a journal of neurology.